Acetylcholinesterase inhibitors (AChEIs) are pivotal in managing Alzheimer's disease and other dementias by impeding the enzyme acetylcholinesterase. This enzyme normally degrades acetylcholine, a neurotransmitter crucial for cognitive functions like memory and learning. In Alzheimer's, a deficit of acetylcholine arises from the loss of cholinergic neurons. AChEIs help sustain higher acetylcholine levels in the brain, offering temporary relief from cognitive symptoms such as memory loss and confusion. While they do not halt or reverse disease progression, these medications can significantly enhance quality of life. Common AChEIs include donepezil, rivastigmine, and galantamine, each with potential side effects like nausea and insomnia. Effective management requires ongoing monitoring and adjustments by healthcare providers to optimize therapeutic benefits.
Jacqueline Tuppen
Cogs Club, United Kingdom
Yong Xiao Wang
Albany Medical College, United States
Kaoru Sakatani
The University of Tokyo, Japan
Suren A Tatulian
University of Central Florida, United States
Constantina Mizis
The Latino Alzheimer’s and Memory Disorders Alliance, United States
Paul Y Song
NKGen Biotech, United States
Marco Ruggiero
Silver Spring Sagl, Switzerland
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Cogs Club: Making a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States